Cellusion CEO Shin Hatou will speak on “Research and development of new corneal regenerative medicine using iPS cells” at the Minaris Regenerative Medicine’s luncheon seminar at the 23rd Congress of the Japanese Society for Regenerative Medicine on March 23, 2024.

Cellusion Director and Executive Appointments

Announcement of Head Quarters Relocation
and Establishment of New Laboratory

Cellusion Receives U.S. FDA Orphan Drug Designation for CLS001

Cellusion CEO, Dr. Shin Hatou received the METI Minister’s Award at the 23rd Japan Venture Awards

Announcement on Appointment of Officers

Cellusion has been selected for the AMED subsidy program

The core technology patent for Cellusion’s development product CLS001,
“METHOD FOR DERIVING CORNEAL ENDOTHELIUM REPLACEMENT CELLS FROM IPS CELLS” was granted in Japan

Cellusion will exhibit at “Genesis 2023” in London

Cellusion CFO Takuya Kaneko will join the “GROWTH INDUSTRY CONFERENCE 2023” pitch contest on November 16.